期刊文献+

同期放化疗加巩固化疗治疗Ⅲ~Ⅳa期鼻咽癌的临床分析 被引量:5

Concurrent chemoradiotherapy plus adjuvant chemotherapy for patients with nasopharyngeal carcinoma of stage Ⅲ and Ⅳa
下载PDF
导出
摘要 目的:观察同期放化疗加巩固化疗治疗Ⅲ~Ⅳa期鼻咽癌的临床疗效及其毒副反应。方法:2010年1月至2011年6月对48例Ⅲ~Ⅳa期鼻咽癌采取同期放化疗加巩固化疗。同期放疗采用常规连续分割放疗,鼻咽部DT70~78Gy/7~8周,颈部DT60~70Gy/6~7周;化疗分为:吉西他滨组:吉西他滨350mg/m2于放疗期间第1、8、15、29、36、43天静脉注射,放疗结束后改为吉西他滨1000mg/m2第1、8、15天,每4周重复,共两疗程;顺铂组:顺铂80mg/m2于放疗期间的第1、22、43天静脉注射,放疗结束后改为顺铂80mg/m2第1天、氟尿嘧啶800mg/m2d第1~5天,每4周重复,共两疗程。放疗后巩固化疗分别于第4、5、6周后进行并分为3组:4周后组、5周后组和6周后组。结果:48例患者中,吉西他滨组总有效率(CR+PR)为95.7%,顺铂组为92.0%,两者差异无统计学意义(P=0.602)。主要毒副作用是骨髓抑制、胃肠道反应和放射性口腔黏膜炎,其他毒副作用均较轻,可耐受。结论:使用低剂量吉西他滨同期放化疗,然后足量吉西他滨巩固化疗治疗Ⅲ~Ⅳa期鼻咽癌是一较好方案,毒副反应较轻。 Objective To observe the efficacy and toxicity of concurrent chemoradiotherapy plus adjuvant chemotherapy for nasopharyngeal carcinoma of stage Ⅲ and Ⅵa.Methods 48 patients with nasopharyngeal carcinoma of stage Ⅲ and Ⅳa were administered with concurrent chemoradiotherapy plus adjuvant chemotherapy.The prescribed radiation regimen was 70 ~ 78 Gy/7 ~ 8 week to nasopharynx,60 ~ 70 Gy/6 ~ 7 week to cervical metastatic focus.The patients were treated with gemcitabine(gemcitabine group) or cisplatin(cisplatin group).Patients in gemcitabine group received concurrent gemcitabine(350 mg/m2 on day 1,8,15,29,36,43) during radiation therapy,followed by gemcitabine(1 000 mg/m2 on day 1,8,15) every 4 weeks for 2 cycles.And patients in cisplatin group received concurrent cisplatin(350 mg/m2 on day 1,22,43) during radiation therapy,followed by cisplatin(80 mg/m2 on day 1) and fluorouracil(800 mg/m2 on days 1 to 5) every 4 weeks for 2 cycles.The adjuvant chemotherapy was administered in the 4th,5th,or 6th week after radiation therapy.Results The total response rates in the gemcitabine and cisplatin groups were 95.7% and 92%(P = 0.602).Toxicity was mainly shown as myelosuppression,gastrointestinal response,and oral mucositis,and other toxicity was relatively lighter.After symptomatic treatment,all the patients could tolerate these toxicities and finished the chemoradiotherapy.Conclusion Gemcitabine offers a satisfactory clinical activity and an acceptable safety profile in patients with nasopharyngeal carcinoma of stage Ⅲ and Ⅵa.
出处 《实用医学杂志》 CAS 北大核心 2012年第20期3367-3369,共3页 The Journal of Practical Medicine
基金 广东省医学科研基金立项资助课题(编号:A2010279)
关键词 鼻咽癌 放射治疗 化学治疗 Nasopharynx Radiotherapy Chemotherapy
  • 相关文献

参考文献9

  • 1Chua D T, Sham J S, Wei W I, et al. The predictive value of the 1997 American joint committee on cancer stage classification in determining failure patterns in nasopharyngeal carcinoma [J]. Cancer, 2001,92(12) : 2845-2855. 被引量:1
  • 2Al-sarraf M, Leblane M, Giri P G, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer phase Ⅲ randomized intergroup study 0099 [J]. J Clin Oncol, 1998,16(4) : 1310-1317. 被引量:1
  • 3Palazi M, Orlandi E, Bossi P, et al. Further improvement in out-comes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy: an update of the milan experince [J]. Int J Radiation Oncology Biol Phys, 2009,74 (3) : 774-780. 被引量:1
  • 4Lee A W, Lau W H, Tung S Y, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group [J]. J Clin Oncol, 2005,23(28):6966-6975. 被引量:1
  • 5Tan E H, Chua E T, Wee J, et al. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in Asian patients with nasopharyngeal carcinoma: toxicities and preliminary results [J]. Int J Radiat Oncol Biol Phys, 1999,45(3):597-601. 被引量:1
  • 6田野,蔡清淟,岑信棠.局部晚期鼻咽癌同期放化疗的疗效分析[J].中华肿瘤杂志,2005,27(7):429-431. 被引量:16
  • 7蔡凯,韦赤勇,杨立华,董彤,刘俊波,胡联民,陈刚,陈勇文,胡奇友.局部晚期鼻咽癌同步放化疗的前瞻性临床研究[J].实用医学杂志,2011,27(23):4226-4228. 被引量:9
  • 8Mala B, Lillian L S, Gregory R P, et al. Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status [J]. Int J Radiat Oncol Biol Phys, 2004,60(4):1127- 1136. 被引量:1
  • 9王希成,韩非.放疗联合吉西他滨治疗局部晚期鼻咽癌的临床研究[J].实用癌症杂志,2009,24(3):285-287. 被引量:6

二级参考文献25

  • 1易俊林,高黎,黄晓东,李素艳,罗京伟,徐国镇.鼻咽癌放射治疗的失败模式[J].中华放射肿瘤学杂志,2004,13(3):145-148. 被引量:89
  • 2吴洁清,路平,寇小格,牛红蕊,苗战会.健择联合顺铂治疗初治进展期食管癌II期临床研究[J].中国民康医学,2005,17(7):360-361. 被引量:2
  • 3高黎.鼻咽癌[M]//殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学.4版.北京:中国协和医科大学出版社,2008:443-484. 被引量:1
  • 4Hareyama M, Sakata K, Shirato H, et al. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma [J]. Cancer, 2002,94(8) :2217-2223. 被引量:1
  • 5Chi K H, Chang Y C, Guo W Y, et al. A phase Ⅲ study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients [J]. Int J Radiat Oncol Biol Phys, 2002, 52 (5): 1238-1244. 被引量:1
  • 6Lin J C, Jan J S, Hsu C Y, et al. Phase Ⅲ study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival [J]. J Clin Oncol, 2003,21 (4):631- 637. 被引量:1
  • 7Zhang L, standard treatment Zhao C, Peng P J, et al. Phase Ⅲ study comparing radiotherapy with or without weekly oxaliplatin in of locoregionally advanced nasopharyngeal carcinoma: preliminary results [J]. J Clin Oncol, 2005,23 (33) : 8641-8647. 被引量:1
  • 8Mould RF, Tai TH. Nasopharyngeal carcinoma: treatments and outcomes in the 20th century. Br J Radiol, 2002, 75: 307-339. 被引量:1
  • 9Al-Sarraf M, LeBlanc M, Giri P, et al. Superiority of five year survival with chemo-radiotherapy (CT-RT) vs radiotherapy in patients with locally advanced nasopharyngeal cancer (NPC) Intergroup (0099) phase Ⅲ study: final report. Proc Am Soc Clin Oncol, 2001, 20:277a. 被引量:1
  • 10Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys, 1995, 31:1341-1346. 被引量:1

共引文献26

同被引文献53

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部